Lack of association of liver fat with model parameters of β-cell function in men with impaired glucose tolerance and type 2 diabetes

European Journal of Endocrinology

Volumn 159, Issue 3, 2008, Pages 251-257

  Tushuizen, Maarten E ^a   Bunck, Mathijs C ^a   Pouwels, Petra J W ^a   Bontemps, Saskia ^a   Mari, Andrea ^a   Diamant, Michaela ^a,b  

^a CNR   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN;

ABDOMINAL OBESITY; ADULT; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FAT CONTENT; FATTY LIVER; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; RISK FACTOR; WAIST CIRCUMFERENCE; ADIPOSE TISSUE; AGED; BIOLOGICAL MODEL; CASE CONTROL STUDY; GLUCOSE INTOLERANCE; LIVER; MIDDLE AGED; PANCREAS ISLET BETA CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; THEORETICAL MODEL;

ADIPOSE TISSUE; ADULT; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; HUMANS; INSULIN-SECRETING CELLS; LIVER; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, THEORETICAL;

EID: 53249149657     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-08-0424     Document Type: Article

References (33)

1. Kotronen A & Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 28 27-38.
2. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T & Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes/Metabolism Research and Reviews 2006 22 437-443.
3. Porte D. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diabetes/Metabolism Research and Reviews 2001 17 181-188.
4. Prentki M & Nolan CJ. Islet β cell failure in type 2 diabetes. Journal of Clinical Investigation 2006 116 1802-1812.
5. Weyer C, Bogardus C, Mott DM & Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Journal of Clinical Investigation 1999 104 787-794.
6. Ferrannini E, Balkan B, Coppack SW, Dekker J, Mari A, Nolan J, Walker M, Natali A, Beck-Nielsen H & the RISC Investigators,. Insulin resistance, insulin response, and obesity as indicators of metabolic risk. Journal of Clinical Endocrinology and Metabolism 2007 92 2885-2892.
7. Tushuizen ME, Bunck MC, Pouwels PJ, Bontemps S, Van Waesberghe JH Mari A, Heine RJ & Diamant M. Pancreatic fat content and β-cell function in men with and without type 2 diabetes. Diabetes Care 2007 30 2916-2921.
8. Wagenknecht LE, Langefeld CD, Scherzinger AL, Norris JM, Haffner SM, Saad MF & Bergman RN. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 2003 52 2490-2496.
9. Utzschneider KM, Carr DB, Hull RL, Kodama K, Shofer JB, Retzlaff BM, Knopp RH & Kahn SE. Impact of intra-abdominal fat and age on insulin sensitivity and beta cell function. Diabetes 2004 53 2867-2872.
10. Gastaldelli A, Sironi AM, Ciociaro D, Positanc, V, Buzzigoli E, Giannessi D, Lombardi M, Mari A & Ferrannini E. Visceral fat and beta cell function in non-diabetic humans. Diabetologia 2005 48 2090-2096.
11. McManus RM, Cunningham I, Watson A, Harker L & Finegood DT. Beta-cell function and visceral fat in lactating women with a history of gestational diabetes. Metabolism 2001 50 715-719.
12. Sironi AM, Gastaldelli A, Mari A, Ciociaro D, Positano V, Buzzigoli E, Ghione S, Turchi S, Lombardi M & Ferrannini E. Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension 2004 44 127-133.
13. Kahn SE, Hull RL & Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006 444 840-846.
14. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B & Ferrannini E. Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. American Journal of Physiology. Endocrinology and Metabolism 2002 283 E1159-E1166.
15. Pacini G & Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Practice and Research. Clinical Endocrinology and Metabolism 2003 17 305-322.
16. Provencher SW Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic Resonance in Medicine 1993 30 672-679.
17. Elbers JM, Haumann G, Asscheman H, Scidell JC & Gooren LJ. Reproducibility of fat area measurements in young, non-obese subjects by computerized analysis of magnetic resonance images. International Journal of Obesity and Related Metabolic Disorders 1997 21 1121-1129.
18. Van Canter E, Mestrez F, Sturis J & Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992 41 368-377.
19. Levy JC, Matthews DR & Hermans ME Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998 21 2191-2192.
20. Mari A, Pacini G, Murphy E, Ludvik B & Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001 24 539-548.
21. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R & Zinman B. American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007 30 753-759.
22. Camastra S, Manco M, Mari A, Baldi S, Gastaldelli A, Greco AV, Mingrone G & Ferrannini E. Beta-cell function in morbidly obese subjects during free living: long-term effects of weight loss. Diabetes 2005 54 2382-2389.
23. Carr DB, Utzschneider KM, Boyko EJ, Asberry PJ, Hull RL, Kodama K, Callahan HS, Matthys CC, Leonetti DL, Schwartz RS, Kahn SE & Fujimoto WY. A reduced-fat diet and aerobic exercise in Japanese Americans with impaired glucose tolerance decreases intra-abdominat fat and improves insulin sensitivity but not β-cell function. Diabetes 2005 54 340-347.
24. Tiikkainen M, Bergholm R, Vehkavaara S, Rissanen A, Hakkinen AM, Tamminen M, Teramo K & Yki-Jarvinen H. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003 52 701-707.
25. Greenberg AS & McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. European Journal of Clinical Investigation 2002 32 (Suppl 3) 24-34.
26. Hu FB, Meigs JB, Li TY, Rifai N & Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004 53 693-700.
27. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC & Lindsay RS. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003 26 1745-1751.
28. Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C & Tataranni PA. High alanine ammotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002 51 1189-1895.
29. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Kempf J, Zinman B & Haffner SM. Elevations in markers of liver injury and risk of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2004 53 2623-2632.
30. Sattar N, Scherbakova O, Ford I. O'Reilly DS, Stanley A, Forrest E, Macfarlane PW Packard CJ, Cobbe SM & Shepherd J. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes 2004 53 2855-2860.
31. Schindhelm RK, Dekker JM, Nijpels G, Heine RJ & Diamant M. No independent association of alanine aminotransferase with risk of future type 2 diabetes in the Hoorn Study. Diabetes Care 2005 28 2812.
32. Nannipieri M, Gonzalez C, Baldi S, Posadas R, Williams K, Haffner SM, Stern MP & Ferrannini E. Liver enzymes, the metabolic syndrome and incident diabetes: the Mexico City Diabetes Study. Diabetes Care 2005 28 1757-1762.
33. Westerbacka J, Kolak M, Kiviluoto, T, Arkkila P, Sirén J, Hamsten A, Fisher RM & Yki-Jarvinen H. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 2007 56 2759-2765.